3-cyclohexyl-2-(4-cyclopropylsulfonyl-2-oxopiperazin-1-yl)-N-(1,3-thiazol-2-yl)propanamide | 1428663-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-cyclohexyl-2-(4-cyclopropylsulfonyl-2-oxopiperazin-1-yl)-N-(1,3-thiazol-2-yl)propanamide
• CAS: 1428663-13-1
• 化学式: C₁₉H₂₈N₄O₄S₂
• 分子量: 440.588
• InChiKey: UVQDJQMAEVSBJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  136
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-boc-dl-3-环己基丙氨酸 在 盐酸 、 4-二甲氨基吡啶 、 potassium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-cyclohexyl-2-(4-cyclopropylsulfonyl-2-oxopiperazin-1-yl)-N-(1,3-thiazol-2-yl)propanamide
  参考文献：
  名称：

  Design, synthesis and SAR of novel glucokinase activators

  摘要：

  Guided by co-crystal structures of compounds 15, 22 and 30, an SBDD approach led to the discovery of the 6-methyl pyridone series as a novel class of GKAs that potently activate GK in enzyme and cell assays. Anti-diabetic OGTT efficacy was demonstrated with 54 in a mouse model of type 2 diabetes. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.093

文献信息

• GLUCOKINASE ACTIVATORS
  申请人：Cheruvallath Zacharia

  公开号：US20090099163A1

  公开（公告）日：2009-04-16

  Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供用于葡萄糖激酶的化合物，其化学式为：其中变量如本文所定义。还提供了包含这些化合物的药物组合物、工具包和制造物品；用于制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• US8173645B2
  申请人：——

  公开号：US8173645B2

  公开（公告）日：2012-05-08
• [EN] GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE GLUCOKINASE
  申请人：TAKEDA SAN DIEGO INC

  公开号：WO2008116107A2

  公开（公告）日：2008-09-25

  [EN] Compounds are provided for use with glucokinase that comprise the formula (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
  [FR] L'invention concerne des composés à utiliser pour réguler la glucokinase de formule (I) dans laquelle les variables sont telles que définies ici. L'invention concerne également des compositions pharmaceutiques, des trousses et des articles de fabrication comprenant de tels composés ; des procédés et des intermédiaires utiles pour préparer les composés ; et des procédés d'utilisation desdits composés.
• Design, synthesis and SAR of novel glucokinase activators
  作者：Zacharia S. Cheruvallath、Stephen L. Gwaltney、Mark Sabat、Mingnam Tang、Jun Feng、Haixia Wang、Joanne Miura、Prasuna Guntupalli、Andy Jennings、David Hosfield、Bumsup Lee、Yiqin Wu

  DOI：10.1016/j.bmcl.2013.01.093

  日期：2013.4

  Guided by co-crystal structures of compounds 15, 22 and 30, an SBDD approach led to the discovery of the 6-methyl pyridone series as a novel class of GKAs that potently activate GK in enzyme and cell assays. Anti-diabetic OGTT efficacy was demonstrated with 54 in a mouse model of type 2 diabetes. (C) 2013 Elsevier Ltd. All rights reserved.